OnCo
companiesCompany

Guardant Health

Liquid biopsy leader: Guardant360 for genotyping, Reveal for MRD, Shield for screening.

Guardant360 CDx (companion for elacestrant, others), Guardant Reveal (tumour-naive MRD), Shield (FDA-approved CRC screening, MCD extension).

Headquarters
Palo Alto, CA, US
Type
diagnostics · GH

Products

1top
ApprovedBlood-based colorectal cancer screening test
Shield

The first FDA-approved blood test for colorectal cancer screening (2024), now optionally reporting other cancers too.

Connected

26top

cancers

1
Colorectal cancer

fronts

2
Diagnostics & BiomarkersEarly Detection & Screening

technologies

5
Comprehensive genomic profilingContinuous and near-continuous ctDNA monitoringLiquid biopsy (ctDNA)MRD / molecular residual disease testingMulti-cancer early detection (MCED)

drugs

1
ApprovedBlood-based colorectal cancer screening test
Shield

ideas

11
An annual blinded shoot-out for liquid biopsy testsCertified reference samples to benchmark every tumour-DNA blood testDrop mandatory fresh biopsies where blood or archival tissue would doEvery tumour genomic report machine-readable and deposited nationallyEvery tumour sequencing report lists open, nearby, matched trials pulled liveKill combination arms early using circulating tumour DNA, before waiting for scansLabel every targetable mutation as truncal or branch on the reportOffer the blood test for bowel cancer only to people who refuse stool tests or colonoscopyOne open atlas of how tumours escape every drugReference materials and open proficiency testing for residual disease testsUse tumour DNA in blood to decide when to pause treatment in metastatic cancer

bottlenecks

6
Data silosDormant cells and minimal residual diseaseFragmented care and guideline gapsMost lethal cancers are found lateTumour heterogeneity and clonal evolutionWeak real-world evidence and registries